表面活性蛋白A单核苷酸基因多态性与过敏性鼻炎皮下特异性免疫治疗疗效相关性分析  

Analysis of associations between surfactant protein A(SP-A) gene single nucleotide polymorphism and specific subcutaneous immunotherapy efficacy for allergic rhinitis

作　　者：何勇[1] 徐博怀 汤继元 余璐洁 张彬[1] HE Yong;XU Bo-Huai;TANG Ji-Yuan;YU Lu-Jie;ZHANG Bin(The Affiliated Hospital of Medical School of Ningbo University,Ningbo 315020,China)

机构地区：[1]宁波大学医学院附属医院,宁波315020 [2]宁波大学,宁波315020

出　　处：《中国免疫学杂志》2020年第6期733-738,743,共7页Chinese Journal of Immunology

基　　金：宁波市医学科技计划项目(2016A13);宁波市科技惠民项目(2017C50051)。

摘　　要：目的:探讨表面活性蛋白A基因单核苷酸多态性与过敏性鼻炎皮下特异性免疫治疗疗效相关性分析。方法:前瞻性募集接受皮下特异性免疫治疗的过敏性鼻炎患者160例,随访1年,记录治疗前、治疗后5个月、治疗后1年过敏性鼻炎症状评分,根据治疗疗效分为好转组和未好转组。提取外周血基因组DNA。采用TaqMan MGB探针技术对表面活性蛋白A基因上的9个标签(rs1059047、rs1136450、rs1136451、rs1059057、rs4253527、rs1059046、rs17886395、rs1965407、rs1965708)进行基因分型。比较两组之间基因型和等位基因分布差异的显著性。结果:共119例患者完成随访,好转组81例,未好转组38例,好转率68%。-50C>G位点(rs1136450)CC基因型患者免疫治疗有效率明显高于GG基因型患者(P<0.05);-223A>C位点(rs1965708)AC基因型患者免疫治疗有效率显著高于AA型患者(P<0.05),其余位点基因型(rs1059047、rs1136451、rs1059057、rs4253527、rs1059046、rs17886395、rs1965407)与免疫治疗有效率无显著相关性。结论:表面活性蛋白A可能是与SCIT治疗效果有关联的易感基因,-50C>G位点(rs1136450),-223A>C位点(rs1965708)多态性可能与过敏性鼻炎皮下特异性免疫治疗疗效有关。Objective:To investigate the associations between surfactant protein A(SP-A)gene single nucleotide polymorphisms(SNPs)and subcutaneous immunotherapy efficacy for the treatment of allergic rhinitis(AR)patients.Methods:The trial was a prospective study involving 160 AR patients who signed to receive subcutaneous immunotherapy(SCIT).These patients were follow-up for 12 months.Clinical efficacy was evaluated by the visual analogue scale(VAS)before the treatment and again after treatment we evaluated at 5 months and 1 year.According to the treatment results,the patients were divided into two groups:clinic improvement group and nonhealing group.SNPs in the SP-A gene(rs1059047,rs1136450,rs1136451,rs1059057,rs4253527,rs1059046,rs17886395,rs1965407,rs1965708)were detected using TaqMan MGB allelic discrimination method from whole blood.Results:119 cases were completely investigated,81 cases divided into clinic improvement group and 38 cases divided into nonhealing group.The total improvement rate was 68%.AR patients with GG genotype of-50C>G site(rs1136450)had higher VAS scores after treatment than those with GG genotype and patients with AC genotype of-223A>C site(rs1965708)had higher VAS scores than those with AA genotype.However,for rs1059047,rs1136451,rs1059057,rs4253527,rs1059046,rs17886395,rs1965407 there were no differences between two groups.Conclusion:Our findings provide evidence that-50C>G site(rs1136450)and-223A>C site(rs1965708)polymorphisms may be associated with subcutaneous immunotherapy efficacy for the treatment of allergic rhinitis(AR)patients.

关 键 词：过敏性鼻炎 表面活性蛋白A 基因多态性 皮下免疫治疗 特异性免疫治疗 疗效 

分 类 号：R392.8[医药卫生—免疫学]